Trial Profile

Phase I/II study assessing early clinical evaluation of potential synergy of targeted radiotherapy with lintuzumab-Ac225 and venetoclax in relapsed/Refractory acute myeloid leukemia (AML)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lintuzumab Ac-225 (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions; Therapeutic Use

12 Dec 2023 Results (n=18) reporting safety and early efficacy data from phase 1 portion of this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition
11 Dec 2023 Results presented in an Actinium Pharmaceuticals media release.
11 Dec 2023 According to Actinium Pharmaceuticals media release, the company highlighted the updated results from phase 1 at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com